Detalhe da pesquisa
1.
Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer.
Anticancer Res
; 28(1B): 507-13, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18383893
2.
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Clin Cancer Res
; 13(21): 6518-26, 2007 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17975165
3.
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
Oncol Res
; 15(1): 39-48, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15839304
4.
Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
Curr Med Chem Anticancer Agents
; 4(2): 123-38, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15032718
5.
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Eur J Pharmacol
; 473(2-3): 83-95, 2003 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-12892825
6.
In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Oncol Rep
; 11(2): 407-14, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14719076
7.
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
J Thorac Oncol
; 3(10): 1104-11, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18827605
8.
Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer.
Clin Chem
; 51(7): 1313-4, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15976131
9.
Histone deacetylation inhibitors.
Suppl Tumori
; 1(4): S52-4, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12415821